Journal of Clinical Epidemiology
Volume 63, Issue 8 , Pages e1-e37 , August 2010

CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials

  • David Moher

      Affiliations

    • Ottawa Methods Centre, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa Hospital, Ottawa, Ontario, Canada, K1H 8L6
    • Corresponding Author InformationCorrespondence to: D Moher.
    • ,
  • Sally Hopewell

      Affiliations

    • Centre for Statistics in Medicine, University of Oxford, Wolfson College, Oxford
    • ,
  • Kenneth F. Schulz

      Affiliations

    • Family Health International, Research Triangle Park, NC 27709, USA
    • ,
  • Victor Montori

      Affiliations

    • UK Knowledge and Encounter Research Unit, Mayo Clinic, Rochester, MN, USA
    • ,
  • Peter C. Gøtzsche

      Affiliations

    • The Nordic Cochrane Centre, Rigshospitalet, Blegdamsvej 9, Copenhagen, Denmark
    • ,
  • P.J. Devereaux

      Affiliations

    • McMaster University Health Sciences Centre, Hamilton, Canada
    • ,
  • Diana Elbourne

      Affiliations

    • Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London
    • ,
  • Matthias Egger

      Affiliations

    • Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland
    • ,
  • Douglas G. Altman

      Affiliations

    • Centre for Statistics in Medicine, University of Oxford, Wolfson College, Oxford

,Accepted 8 February 2010.

References 

  1. Rennie D. CONSORT revised—improving the reporting of randomized trials. JAMA. 2001;285:2006–2007
  2. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408–412
  3. Moher D. CONSORT: an evolving tool to help improve the quality of reports of randomized controlled trials. Consolidated Standards of Reporting Trials. JAMA. 1998;279:1489–1491
  4. Kjaergard LL, Villumsen J, Gluud C. Quality of randomised clinical trials affects estimates of intervention efficacy. Rome, Italy: 7th Cochrane Colloquium; 1999;
  5. Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ. 2001;323:42–46
  6. Veldhuyzen van Zanten SJ, Cleary C, Talley NJ, Peterson TC, Nyren O, Bradley LA, et al. Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol. 1996;91:660–673
  7. Talley NJ, Owen BK, Boyce P, Paterson K. Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials. Am J Gastroenterol. 1996;91:277–283
  8. Adetugbo K, Williams H. How well are randomized controlled trials reported in the dermatology literature?. Arch Dermatol. 2000;136:381–385
  9. Kjaergard LL, Nikolova D, Gluud C. Randomized clinical trials in HEPATOLOGY: predictors of quality. Hepatology. 1999;30:1134–1138
  10. Schor S, Karten I. Statistical evaluation of medical journal manuscripts. JAMA. 1966;195:1123–1128
  11. Gore SM, Jones IG, Rytter EC. Misuse of statistical methods: critical assessment of articles in BMJ from January to March 1976. BMJ. 1977;1:85–87
  12. Hall JC, Hill D, Watts JM. Misuse of statistical methods in the Australasian surgical literature. Aust N Z J Surg. 1982;52:541–543
  13. Altman DG. Statistics in medical journals. Stat Med. 1982;1:59–71
  14. Pocock SJ, Hughes MD, Lee RJ. Statistical problems in the reporting of clinical trials. A survey of three medical journals. N Engl J Med. 1987;317:426–432
  15. Altman DG. The scandal of poor medical research. BMJ. 1994;308:283–284
  16. Chan AW, Altman DG. Epidemiology and reporting of randomised trials published in PubMed journals. Lancet. 2005;365:1159–1162
  17. Hopewell S, Dutton S, Yu LM, Chan AW, Altman DG. The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed. BMJ. 2010;340:c723
  18. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ. 1999;319:670–674
  19. Lai TY, Wong VW, Lam RF, Cheng AC, Lam DS, Leung GM. Quality of reporting of key methodological items of randomized controlled trials in clinical ophthalmic journals. Ophthalmic Epidemiol. 2007;14:390–398
  20. Moher D, Fortin P, Jadad AR, Juni P, Klassen T, Le LJ, et al. Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews. Lancet. 1996;347:363–366
  21. Junker CA. Adherence to published standards of reporting: a comparison of placebo-controlled trials published in English or German. JAMA. 1998;280:247–249
  22. Altman DG. Randomisation. BMJ. 1991;302:1481–1482
  23. Schulz KF, Chalmers I, Grimes DA, Altman DG. Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals. JAMA. 1994;272:125–128
  24. Streptomycin treatment of pulmonary tuberculosis: a Medical Research Council investigation. BMJ. 1948;2:769–782
  25. Schulz KF. Randomized controlled trials. Clin Obstet Gynecol. 1998;41:245–256
  26. Greenland S. Randomization, statistics, and causal inference. Epidemiology. 1990;1:421–429
  27. Armitage P. The role of randomization in clinical trials. Stat Med. 1982;1:345–352
  28. Kleijnen J, Gotzsche PC, Kunz R, Oxman AD, Chalmers I. So what's so special about randomisation. In:  Maynard A,  Chalmers I editor. Non-random reflections on health services research. BMJ Books; 1997;p. 93–106
  29. Chalmers I. Assembling comparison groups to assess the effects of health care. J R Soc Med. 1997;90:379–386
  30. Nicolucci A, Grilli R, Alexanian AA, Apolone G, Torri V, Liberati A. Quality, evolution, and clinical implications of randomized, controlled trials on the treatment of lung cancer. A lost opportunity for meta-analysis. JAMA. 1989;262:2101–2107
  31. Ah-See KW, Molony NC. A qualitative assessment of randomized controlled trials in otolaryngology. J Laryngol Otol. 1998;112:460–463
  32. Altman DG, Dore CJ. Randomisation and baseline comparisons in clinical trials. Lancet. 1990;335:149–153
  33. Thornley B, Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ. 1998;317:1181–1184
  34. DerSimonian R, Charette LJ, McPeek B, Mosteller F. Reporting on methods in clinical trials. N Engl J Med. 1982;306:1332–1337
  35. A proposal for structured reporting of randomized controlled trials. The Standards of Reporting Trials Group. JAMA. 1994;272:1926–1931
  36. Call for comments on a proposal to improve reporting of clinical trials in the biomedical literature. Working Group on Recommendations for Reporting of Clinical Trials in the Biomedical Literature. Ann Intern Med. 1994;121:894–895
  37. Rennie D. Reporting randomized controlled trials. An experiment and a call for responses from readers. JAMA. 1995;273:1054–1055
  38. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA. 1996;276:637–639
  39. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA. 2006;295:1152–1160
  40. Campbell MK, Elbourne DR, Altman DG. CONSORT statement: extension to cluster randomised trials. BMJ. 2004;328:702–708
  41. Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390
  42. Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141:781–788
  43. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med. 2008;148:295–309
  44. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. Ann Intern Med. 2006;144:364–367
  45. Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, et al. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008;5:e20
  46. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1339–1341
  47. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ. 1996;313:275–283
  48. Lang TA, Secic M. How to report statistics in medicine. Annotated guidelines for authors, editors, and reviewers. ACP. 1997;
  49. Davidoff F. News from the International Committee of Medical Journal Editors. Ann Intern Med. 2000;133:229–231
  50. Plint AC, Moher D, Morrison A, Schulz K, Altman DG, Hill C, et al. Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. Med J Aust. 2006;185:263–267
  51. Egger M, Juni P, Bartlett C. Value of flow diagrams in reports of randomized controlled trials. JAMA. 2001;285:1996–1999
  52. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med. 2001;134:657–662
  53. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001;285:1987–1991
  54. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357:1191–1194
  55. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA. 2004;291:2457–2465
  56. Al-Marzouki S, Roberts I, Evans S, Marshall T. Selective reporting in clinical trials: analysis of trial protocols accepted by the Lancet. Lancet. 2008;372:201
  57. Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan AW, Cronin E, et al. Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS ONE. 2008;3:e3081
  58. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134:663–694
  59. Schulz KF, Altman DG, Moher D for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332
  60. Pocock SJ. Clinical trials: a practical approach. John Wiley; 1983;
  61. Meinert CL. Clinical trials: design, conduct and analysis. Oxford University Press; 1986;
  62. Friedman LM, Furberg CD, DeMets DL. Fundamentals of clinical trials. 3rd ed.. Springer; 1998;
  63. Bolliger CT, Zellweger JP, Danielsson T, van Biljon X, Robidou A, Westin A, et al. Smoking reduction with oral nicotine inhalers: double blind, randomised clinical trial of efficacy and safety. BMJ. 2000;321:329–333
  64. Dickersin K, Manheimer E, Wieland S, Robinson KA, Lefebvre C, McDonald S. Development of the Cochrane Collaboration's CENTRAL Register of controlled clinical trials. Eval Health Prof. 2002;25:38–64
  65. Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, et al. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371:281–283
  66. The impact of open access upon public health. PLoS Med. 2006;3:e252
  67. Harbourt AM, Knecht LS, Humphreys BL. Structured abstracts in MEDLINE, 1989-1991. Bull Med Libr Assoc. 1995;83:190–195
  68. Harris AH, Standard S, Brunning JL, Casey SL, Goldberg JH, Oliver L, et al. The accuracy of abstracts in psychology journals. J Psychol. 2002;136:141–148
  69. Pitkin RM, Branagan MA, Burmeister LF. Accuracy of data in abstracts of published research articles. JAMA. 1999;281:1110–1111
  70. Ward LG, Kendrach MG, Price SO. Accuracy of abstracts for original research articles in pharmacy journals. Ann Pharmacother. 2004;38:1173–1177
  71. Gotzsche PC. Believability of relative risks and odds ratios in abstracts: cross sectional study. BMJ. 2006;333:231–234
  72. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA. 2001;285:437–443
  73. Haynes RB, Mulrow CD, Huth EJ, Altman DG, Gardner MJ. More informative abstracts revisited. Ann Intern Med. 1990;113:69–76
  74. Taddio A, Pain T, Fassos FF, Boon H, Ilersich AL, Einarson TR. Quality of nonstructured and structured abstracts of original research articles in the British Medical Journal, the Canadian Medical Association Journal and the Journal of the American Medical Association. CMAJ. 1994;150:1611–1615
  75. Wager E, Middleton P. Technical editing of research reports in biomedical journals. Cochrane Database Syst Rev. 2008;MR000002
  76. Hartley J, Sydes M, Blurton A. Obtaining information accurately and quickly: Are structured abstracts more efficient?. J Inform Sci. 1996;22:349–356
  77. Gilligan D, Nicolson M, Smith I, Groen H, Dalesio O, Goldstraw P, et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet. 2007;369:1929–1937
  78. Sandler AD, Sutton KA, DeWeese J, Girardi MA, Sheppard V, Bodfish JW. Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N Engl J Med. 1999;341:1801–1806
  79. World Medical Association. Declaration of Helsinki: ethical principle for medical research involving human subjects. 59th WMA General Assembly, Seoul 2008; www.wma.net/e/policy/b3.htm (accessed 2 June 2009).
  80. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med. 1992;327:248–254
  81. Fergusson D, Glass KC, Hutton B, Shapiro S. Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding?. Clin Trials. 2005;2:218–229
  82. Savulescu J, Chalmers I, Blunt J. Are research ethics committees behaving unethically? Some suggestions for improving performance and accountability. BMJ. 1996;313:1390–1393
  83. Sadler LC, Davison T, McCowan LM. A randomised controlled trial and meta-analysis of active management of labour. BJOG. 2000;107:909–915
  84. Bath FJ, Owen VE, Bath PM. Quality of full and final publications reporting acute stroke trials: a systematic review. Stroke. 1998;29:2203–2210
  85. Blumer JL, Findling RL, Shih WJ, Soubrane C, Reed MD. Controlled clinical trial of zolpidem for the treatment of insomnia associated with attention-deficit/hyperactivity disorder in children 6 to 17 years of age. Pediatrics. 2009;123:e770–e776
  86. Sabatine MS, Antman EM, Widimsky P, Ebrahim IO, Kiss RG, Saaiman A, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2009;374:787–795
  87. Grant AM, Altman DG, Babiker AB, Campbell MK, Clemens FJ, Darbyshire JH, et al. Issues in data monitoring and interim analysis of trials. Health Technol Assess. 2005;9:1-iv
  88. Gallo P, Krams M. PhRMA Working Group on adaptive designs, “White Paper.”. Drug Information Journal. 2006;40:421–482
  89. Brown CH, Ten Have TR, Jo B, Dagne G, Wyman PA, Muthen B, et al. Adaptive designs for randomized trials in public health. Annu Rev Public Health. 2009;30:1–25
  90. Kelly PJ, Sooriyarachchi MR, Stallard N, Todd S. A practical comparison of group-sequential and adaptive designs. J Biopharm Stat. 2005;15:719–738
  91. Pildal J, Chan AW, Hrobjartsson A, Forfang E, Altman DG, Gotzsche PC. Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study. BMJ. 2005;330:1049
  92. Chan AW, Hrobjartsson A, Jorgensen KJ, Gotzsche PC, Altman DG. Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols. BMJ. 2008;337:a2299
  93. Ndekha MJ, van Oosterhout JJ, Zijlstra EE, Manary M, Saloojee H, Manary MJ. Supplementary feeding with either ready-to-use fortified spread or corn-soy blend in wasted adults starting antiretroviral therapy in Malawi: randomised, investigator blinded, controlled trial. BMJ. 2009;338:1867–1875
  94. Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet. 2005;365:82–93
  95. Fuks A, Weijer C, Freedman B, Shapiro S, Skrutkowska M, Riaz A. A study in contrasts: eligibility criteria in a twenty-year sample of NSABP and POG clinical trials. National Surgical Adjuvant Breast and Bowel Program. Pediatric Oncology Group. J Clin Epidemiol. 1998;51:69–79
  96. Shapiro SH, Weijer C, Freedman B. Reporting the study populations of clinical trials. Clear transmission or static on the line?. J Clin Epidemiol. 2000;53:973–979
  97. Gandhi M, Ameli N, Bacchetti P, Sharp GB, French AL, Young M, et al. Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols. AIDS. 2005;19:1885–1896
  98. Hall JC, Mills B, Nguyen H, Hall JL. Methodologic standards in surgical trials. Surgery. 1996;119:466–472
  99. Weiss NS, Koepsell TD, Psaty BM. Generalizability of the results of randomized trials. Arch Intern Med. 2008;168:133–135
  100. Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, Villar JC, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet. 2008;371:1839–1847
  101. Rannou F, Dimet J, Boutron I, Baron G, Fayad F, Mace Y, et al. Splint for base-of-thumb osteoarthritis: a randomized trial. Ann Intern Med. 2009;150:661–669
  102. Glasziou P, Meats E, Heneghan C, Shepperd S. What is missing from descriptions of treatment in trials and reviews?. BMJ. 2008;336:1472–1474
  103. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385–390
  104. McDowell I, Newell C. Measuring health: a guide to rating scales and questionnaires. 3rd ed.. New York: Oxford University Press; 2006;
  105. Streiner D, Norman C. Health measurement scales: a practical guide to their development and use. 3rd ed.. Oxford: Oxford University Press; 2003;
  106. Clarke M. Standardising outcomes for clinical trials and systematic reviews. Trials. 2007;8:39
  107. Sanders C, Egger M, Donovan J, Tallon D, Frankel S. Reporting on quality of life in randomised controlled trials: bibliographic study. BMJ. 1998;317:1191–1194
  108. Gotzsche PC. Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Control Clin Trials. 1989;10:31–56
  109. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. Br J Psychiatry. 2000;176:249–252
  110. Jadad AR, Boyle M, Cunnigham C, Kim M, Schachar R. Treatment of Attention-Deficit/Hyperactivity Disorder. Evidence Report/Technology Assessment No. 11. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Healthcare Research and Quality. AHQR publication no. 00-E005; 1999;
  111. Schachter HM, Pham B, King J, Langford S, Moher D. The efficacy and safety of methylphenidate in attention deficit disorder: A systematic review and meta-analyis. Prepared for the Therapeutics Inititiative, Vancouver, B.C., and the British Columbia Ministry for Children and Families, 2000.
  112. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385–1390
  113. Chan AW, Krleza-Jeric K, Schmid I, Altman DG. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. CMAJ. 2004;171:735–740
  114. Vermeulen H, Hofland J, Legemate DA, Ubbink DT. Intravenous fluid restriction after major abdominal surgery: a randomized blinded clinical trial. Trials. 2009;10:50
  115. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807–816
  116. Campbell MJ, Julious SA, Altman DG. Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons. BMJ. 1995;311:1145–1148
  117. Guyatt GH, Mills EJ, Elbourne D. In the era of systematic reviews, does the size of an individual trial still matter. PLoS Med. 2008;5:e4
  118. Schulz KF, Grimes DA. Sample size calculations in randomised trials: mandatory and mystical. Lancet. 2005;365:1348–1353
  119. Halpern SD, Karlawish JH, Berlin JA. The continuing unethical conduct of underpowered clinical trials. JAMA. 2002;288:358–362
  120. Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ. 1995;311:485
  121. Moher D, Dulberg CS, Wells GA. Statistical power, sample size, and their reporting in randomized controlled trials. JAMA. 1994;272:122–124
  122. Freiman JA, Chalmers TC, Smith H, Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. N Engl J Med. 1978;299:690–694
  123. Charles P, Giraudeau B, Dechartres A, Baron G, Ravaud P. Reporting of sample size calculation in randomised controlled trials: review. BMJ. 2009;338:b1732
  124. Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials?. Stat Med. 1984;3:409–422
  125. Goodman SN, Berlin JA. The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. Ann Intern Med. 1994;121:200–206
  126. Galgiani JN, Catanzaro A, Cloud GA, Johnson RH, Williams PL, Mirels LF, et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group. Ann Intern Med. 2000;133:676–686
  127. Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360:2066–2078
  128. Geller NL, Pocock SJ. Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners. Biometrics. 1987;43:213–223
  129. Berry DA. Interim analyses in clinical trials: classical vs. Bayesian approaches. Stat Med. 1985;4:521–526
  130. Pocock SJ. When to stop a clinical trial. BMJ. 1992;305:235–240
  131. DeMets DL, Pocock SJ, Julian DG. The agonising negative trend in monitoring of clinical trials. Lancet. 1999;354:1983–1988
  132. Buyse M. Interim analyses, stopping rules and data monitoring in clinical trials in Europe. Stat Med. 1993;12:509–520
  133. Sydes MR, Altman DG, Babiker AB, Parmar MK, Spiegelhalter DJ. Reported use of data monitoring committees in the main published reports of randomized controlled trials: a cross-sectional study. Clin Trials. 2004;1:48–59
  134. Montori VM, Devereaux PJ, Adhikari NK, Burns KE, Eggert CH, Briel M, et al. Randomized trials stopped early for benefit: a systematic review. JAMA. 2005;294:2203–2209
  135. Coutinho IC, Ramos de Amorim MM, Katz L, Bandeira de Ferraz AA. Uterine exteriorization compared with in situ repair at cesarean delivery: a randomized controlled trial. Obstet Gynecol. 2008;111:639–647
  136. Juni P, Altman DG, Egger M. Assessing the quality of controlled clinical trials. In:  Egger M,  Davey Smith G,  Altman DG editor. Systematic reviews in health care: meta-analysis in context. BMJ Books; 2001;
  137. Creinin MD, Meyn LA, Borgatta L, Barnhart K, Jensen J, Burke AE, et al. Multicenter comparison of the contraceptive ring and patch: a randomized controlled trial. Obstet Gynecol. 2008;111:267–277
  138. Tate DF, Jackvony EH, Wing RR. Effects of internet behavioral counseling on weight loss in adults at risk for type 2 diabetes: a randomized trial. JAMA. 2003;289:1833–1836
  139. Lachin JM. Properties of simple randomization in clinical trials. Control Clin Trials. 1988;9:312–326
  140. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer. 1976;34:585–612
  141. Schulz KF, Grimes DA. The Lancet handbook of essential concepts in clinical research. Elsevier; 2006;
  142. Altman DG, Bland JM. How to randomise. BMJ. 1999;319:703–704
  143. Schulz KF. Subverting randomization in controlled trials. JAMA. 1995;274:1456–1458
  144. Enas GG, Enas NH, Spradlin CT, Wilson MG, Wiltse CG. Baseline comparability in clinical trials: prevention of poststudy anxiety. Drug Information Journal. 1990;24:541–548
  145. Treasure T, MacRae KD. Minimisation: the platinum standard for trials? Randomisation doesn't guarantee similarity of groups; minimisation does. BMJ. 1998;317:362–363
  146. Sinei SK, Schulz KF, Lamptey PR, Grimes DA, Mati JK, Rosenthal SM, et al. Preventing IUCD-related pelvic infection: the efficacy of prophylactic doxycycline at insertion. Br J Obstet Gynaecol. 1990;97:412–419
  147. Radford JA, Landorf KB, Buchbinder R, Cook C. Effectiveness of low-Dye taping for the short-term treatment of plantar heel pain: a randomised trial. BMC Musculoskelet Disord. 2006;7:64
  148. Chalmers TC, Levin H, Sacks HS, Reitman D, Berrier J, Nagalingam R. Meta-analysis of clinical trials as a scientific discipline. I: Control of bias and comparison with large co-operative trials. Stat Med. 1987;6:315–328
  149. Pocock SJ. Statistical aspects of clinical trial design. Statistician. 1982;31:1–18
  150. Haag U. Technologies for automating randomized treatment assignment in clinical trials. Drug Information Journal. 1998;32:11
  151. Piaggio G, Elbourne D, Schulz KF, Villar J, Pinol AP, Gulmezoglu AM. The reporting of methods for reducing and detecting bias: an example from the WHO Misoprostol Third Stage of Labour equivalence randomised controlled trial. BMC Med Res Methodol. 2003;3:19
  152. Pildal J, Hrobjartsson A, Jorgensen KJ, Hilden J, Altman DG, Gotzsche PC. Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. Int J Epidemiol. 2007;36:847–857
  153. Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ. 2008;336:601–605
  154. McCandlish R, Bowler U, van Asten H, Berridge G, Winter C, Sames L, et al. A randomised controlled trial of care of the perineum during second stage of normal labour. Br J Obstet Gynaecol. 1998;105:1262–1272
  155. Webster J, Clarke S, Paterson D, Hutton A, van Dyk S, Gale C, et al. Routine care of peripheral intravenous catheters versus clinically indicated replacement: randomised controlled trial. BMJ. 2008;337:a339
  156. Smith SA, Shah ND, Bryant SC, Christianson TJ, Bjornsen SS, Giesler PD, et al. Chronic care model and shared care in diabetes: randomized trial of an electronic decision support system. Mayo Clin Proc. 2008;83:747–757
  157. Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009;360:859–873
  158. Kaptchuk TJ. Intentional ignorance: a history of blind assessment and placebo controls in medicine. Bull Hist Med. 1998;72:389–433
  159. Guyatt GH, Pugsley SO, Sullivan MJ, Thompson PJ, Berman L, Jones NL, et al. Effect of encouragement on walking test performance. Thorax. 1984;39:818–822
  160. Gotzsche PC. Blinding during data analysis and writing of manuscripts. Control Clin Trials. 1996;17:285–290
  161. Karlowski TR, Chalmers TC, Frenkel LD, Kapikian AZ, Lewis TL, Lynch JM. Ascorbic acid for the common cold. A prophylactic and therapeutic trial. JAMA. 1975;231:1038–1042
  162. Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E, Roberts R. The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology. 1994;44:16–20
  163. Carley SD, Libetta C, Flavin B, Butler J, Tong N, Sammy I. An open prospective randomised trial to reduce the pain of blood glucose testing: ear versus thumb. BMJ. 2000;321:20
  164. Schulz KF, Chalmers I, Altman DG. The landscape and lexicon of blinding in randomized trials. Ann Intern Med. 2002;136:254–259
  165. Day SJ, Altman DG. Statistics notes: blinding in clinical trials and other studies. BMJ. 2000;321:504
  166. Montori VM, Bhandari M, Devereaux PJ, Manns BJ, Ghali WA, Guyatt GH. In the dark: the reporting of blinding status in randomized controlled trials. J Clin Epidemiol. 2002;55:787–790
  167. Cheng K, Smyth RL, Motley J, O'Hea U, Ashby D. Randomized controlled trials in cystic fibrosis (1966-1997) categorized by time, design, and intervention. Pediatr Pulmonol. 2000;29:1–7
  168. Lang T. Masking or blinding? An unscientific survey of mostly medical journal editors on the great debate. Med Gen Med. 2000;2:E25
  169. Devereaux PJ, Manns BJ, Ghali WA, Quan H, Lacchetti C, Montori VM, et al. Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials. JAMA. 2001;285:2000–2003
  170. Haahr MT, Hrobjartsson A. Who is blinded in randomized clinical trials? A study of 200 trials and a survey of authors. Clin Trials. 2006;3:360–365
  171. Meinert CL. Masked monitoring in clinical trials—blind stupidity?. N Engl J Med. 1998;338:1381–1382
  172. Mills E, Prousky J, Raskin G, Gagnier J, Rachlis B, Montori VM, et al. The safety of over-the-counter niacin. A randomized placebo-controlled trial [[ISRCTN18054903]]. BMC Clin Pharmacol. 2003;3:4
  173. Schulz KF, Grimes DA, Altman DG, Hayes RJ. Blinding and exclusions after allocation in randomised controlled trials: survey of published parallel group trials in obstetrics and gynaecology. BMJ. 1996;312:742–744
  174. Fergusson D, Glass KC, Waring D, Shapiro S. Turning a blind eye: the success of blinding reported in a random sample of randomised, placebo controlled trials. BMJ. 2004;328:432
  175. Sackett DL. Turning a blind eye: why we don't test for blindness at the end of our trials. BMJ. 2004;328:1136
  176. Astrup A, Rossner S, Van Gaal L, Rissanen A, Niskanen L, Al HM, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374:1606–1616
  177. Altman DG, Gore SM, Gardner MJ, Pocock SJ. Statistical guidelines for contributors to medical journals. In:  Altman DG,  Machin D,  Bryant TN,  Gardner MJ editor. Statistics with confidence: confidence intervals and statistical guidelines. 2nd ed. BMJ Books; 2000;p. 171–190
  178. Altman DG, Bland JM. Statistics notes. Units of analysis. BMJ. 1997;314:1874
  179. Bolton S. Independence and statistical inference in clinical trial designs: a tutorial review. J Clin Pharmacol. 1998;38:408–412
  180. Greenland S. Principles of multilevel modelling. Int J Epidemiol. 2000;29:158–167
  181. Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA. 2008;299:2027–2036
  182. Matthews JN, Altman DG. Interaction 3: How to examine heterogeneity. BMJ. 1996;313:862
  183. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet. 2000;355:1064–1069
  184. Matthews JN, Altman DG. Statistics notes. Interaction 2: Compare effect sizes not P values. BMJ. 1996;313:808
  185. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med. 1992;116:78–84
  186. Steyerberg EW, Bossuyt PM, Lee KL. Clinical trials in acute myocardial infarction: should we adjust for baseline characteristics?. Am Heart J. 2000;139:745–751
  187. Altman DG. Adjustment for covariate imbalance. In:  Armitage P,  Colton T editor. Encyclopedia of biostatistics. John Wiley; 1998;p. 1000–1005
  188. Mullner M, Matthews H, Altman DG. Reporting on statistical methods to adjust for confounding: a cross-sectional survey. Ann Intern Med. 2002;136:122–126
  189. Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. Ann Intern Med. 1993;118:201–210
  190. Bender R, Grouven U. Logistic regression models used in medical research are poorly presented. BMJ. 1996;313:628
  191. Khan KS, Chien PF, Dwarakanath LS. Logistic regression models in obstetrics and gynecology literature. Obstet Gynecol. 1999;93:1014–1020
  192. Sackett DL, Gent M. Controversy in counting and attributing events in clinical trials. N Engl J Med. 1979;301:1410–1412
  193. May GS, DeMets DL, Friedman LM, Furberg C, Passamani E. The randomized clinical trial: bias in analysis. Circulation. 1981;64:669–673
  194. Altman DG, Cuzick J, Peto J. More on zidovudine in asymptomatic HIV infection. N Engl J Med. 1994;330:1758–1759
  195. Meinert CL. Beyond CONSORT: need for improved reporting standards for clinical trials. Consolidated Standards of Reporting Trials. JAMA. 1998;279:1487–1489
  196. Grant AM, Wileman SM, Ramsay CR, Mowat NA, Krukowski ZH, Heading RC, et al. Minimal access surgery compared with medical management for chronic gastro-oesophageal reflux disease: UK collaborative randomised trial. BMJ. 2008;337:a2664
  197. van Loon AJ, Mantingh A, Serlier EK, Kroon G, Mooyaart EL, Huisjes HJ. Randomised controlled trial of magnetic-resonance pelvimetry in breech presentation at term. Lancet. 1997;350:1799–1804
  198. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356:366–372
  199. LaCroix AZ, Ott SM, Ichikawa L, Scholes D, Barlow WE. Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2000;133:516–526
  200. Shuster JJ. Median follow-up in clinical trials. J Clin Oncol. 1991;9:191–192
  201. Altman DG, de Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in cancer journals. Br J Cancer. 1995;72:511–518
  202. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2:e298
  203. Diggle L, Deeks J. Effect of needle length on incidence of local reactions to routine immunisation in infants aged 4 months: randomised controlled trial. BMJ. 2000;321:931–933
  204. Pocock S, White I. Trials stopped early: too good to be true?. Lancet. 1999;353:943–944
  205. Hughes MD, Pocock SJ. Stopping rules and estimation problems in clinical trials. Stat Med. 1988;7:1231–1242
  206. Kiri A, Tonascia S, Meinert CL. Treatment effects monitoring committees and early stopping in large clinical trials. Clin Trials. 2004;1:40–47
  207. Psaty BM, Rennie D. Stopping medical research to save money: a broken pact with researchers and patients. JAMA. 2003;289:2128–2131
  208. Temple R. FDA perspective on trials with interim efficacy evaluations. Stat Med. 2006;25:3245–3249
  209. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174–1183
  210. Senn S. Base logic: tests of baseline balance in randomized clinical trials. Clin Res Regulatory Affairs. 1995;12:171–182
  211. Altman DG. Comparability of randomised groups. Statistician. 1985;34:125–136
  212. Heit JA, Elliott CG, Trowbridge AA, Morrey BF, Gent M, Hirsh J. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2000;132:853–861
  213. Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology. 2000;119:639–646
  214. Fields WS, Maslenikov V, Meyer JS, Hass WK, Remington RD, Macdonald M. Joint study of extracranial arterial occlusion. V. Progress report of prognosis following surgery or nonsurgical treatment for transient cerebral ischemic attacks and cervical carotid artery lesions. JAMA. 1970;211:1993–2003
  215. Lee YJ, Ellenberg JH, Hirtz DG, Nelson KB. Analysis of clinical trials by treatment actually received: is it really an option?. Stat Med. 1991;10:1595–1605
  216. Lewis JA, Machin D. Intention to treat—who should use ITT?. Br J Cancer. 1993;68:647–650
  217. Lachin JL. Statistical considerations in the intent-to-treat principle. Control Clin Trials. 2000;21:526
  218. Sheiner LB, Rubin DB. Intention-to-treat analysis and the goals of clinical trials. Clin Pharmacol Ther. 1995;57:6–15
  219. Nagelkerke N, Fidler V, Bernsen R, Borgdorff M. Estimating treatment effects in randomized clinical trials in the presence of non-compliance. Stat Med. 2000;19:1849–1864
  220. Melander H, hlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine–selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ. 2003;326:1171–1173
  221. Gravel J, Opatrny L, Shapiro S. The intention-to-treat approach in randomized controlled trials: are authors saying what they do and doing what they say?. Clin Trials. 2007;4:350–356
  222. Kruse RL, Alper BS, Reust C, Stevermer JJ, Shannon S, Williams RH. Intention-to-treat analysis: who is in? Who is out?. J Fam Pract. 2002;51:969–971
  223. Herman A, Botser IB, Tenenbaum S, Chechick A. Intention-to-treat analysis and accounting for missing data in orthopaedic randomized clinical trials. J Bone Joint Surg Am. 2009;91:2137–2143
  224. Ruiz-Canela M, Martinez-Gonzalez MA, de Irala-Estevez J. Intention to treat analysis is related to methodological quality. BMJ. 2000;320:1007–1008
  225. Altman DG. Missing outcomes in randomised trials: addressing the dilemma. Open Med. 2009;3:e21–e23
  226. Wood AM, White IR, Thompson SG. Are missing outcome data adequately handled? A review of published randomized controlled trials in major medical journals. Clin Trials. 2004;1:368–376
  227. Streiner DL. Missing data and the trouble with LOCF. Evid Based Ment Health. 2008;11:3–5
  228. Molnar FJ, Hutton B, Fergusson D. Does analysis using "last observation carried forward" introduce bias in dementia research?. CMAJ. 2008;179:751–753
  229. Ware JH. Interpreting incomplete data in studies of diet and weight loss. N Engl J Med. 2003;348:2136–2137
  230. Streiner DL. The case of the missing data: methods of dealing with dropouts and other research vagaries. Can J Psychiatry. 2002;47:68–75
  231. Lane P. Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. Pharm Stat. 2008;7:93–106
  232. Abraha I, Montedori A, Romagnoli C. Modified intention to treat: frequency, definition and implication for clinical trials [abstract]. Sao Paulo, Brazil: XV Cochrane Colloquium; 2007;86-7
  233. Altman DG. Confidence intervals in practice. In:  Altman DG,  Machin D,  Bryant TN,  Gardner MJ editor. Statistics with confidence. 2nd ed. BMJ Books; 2000;p. 6–14
  234. van Linschoten R, van Middelkoop M, Berger MY, Heintjes EM, Verhaar JA, Willemsen SP, et al. Supervised exercise therapy versus usual care for patellofemoral pain syndrome: an open label randomised controlled trial. BMJ. 2009;339:b4074
  235. Altman DG. Clinical trials and meta-analyses. In:  Altman DG,  Machin D,  Bryant TN,  Gardner MJ editor. Statistics with confidence. 2nd ed. BMJ Books; 2000;p. 120–138
  236. Uniform requirements for manuscripts submitted to biomedical journals. International Committee of Medical Journal Editors. Ann Intern Med. 1997;126:36–47
  237. Gardner MJ, Altman DG. Confidence intervals rather than P values: estimation rather than hypothesis testing. BMJ. 1986;292:746–750
  238. Bailar JC, Mosteller F. Guidelines for statistical reporting in articles for medical journals. Amplifications and explanations. Ann Intern Med. 1988;108:266–273
  239. Bland JM. Quoting intermediate analyses can only mislead. BMJ. 1997;314:1907–1908
  240. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310:452–454
  241. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999;319:1492–1495
  242. The OSIRIS Collaborative Group. Early versus delayed neonatal administration of a synthetic surfactant—the judgment of OSIRIS (open study of infants at high risk of or with respiratory insufficiency—the role of surfactant). Lancet. 1992;340:1363–1369
  243. Sorensen L, Gyrd-Hansen D, Kristiansen IS, Nexoe J, Nielsen JB. Laypersons’ understanding of relative risk reductions: randomised cross-sectional study. BMC Med Inform Decis Mak. 2008;8:31
  244. Bobbio M, Demichelis B, Giustetto G. Completeness of reporting trial results: effect on physicians’ willingness to prescribe. Lancet. 1994;343:1209–1211
  245. Naylor CD, Chen E, Strauss B. Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness?. Ann Intern Med. 1992;117:916–921
  246. Tukey JW. Some thoughts on clinical trials, especially problems of multiplicity. Science. 1977;198:679–684
  247. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA. 1991;266:93–98
  248. Hahn S, Williamson PR, Hutton JL, Garner P, Flynn EV. Assessing the potential for bias in meta-analysis due to selective reporting of subgroup analyses within studies. Stat Med. 2000;19:3325–3336
  249. Bhandari M, Devereaux PJ, Li P, Mah D, Lim K, Schunemann HJ, et al. Misuse of baseline comparison tests and subgroup analyses in surgical trials. Clin Orthop Relat Res. 2006;447:247–251
  250. Levin M, Quint PA, Goldstein B, Barton P, Bradley JS, Shemie SD, et al. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet. 2000;356:961–967
  251. Scharf O, Colevas AD. Adverse event reporting in publications compared with sponsor database for cancer clinical trials. J Clin Oncol. 2006;24:3933–3938
  252. Pitrou I, Boutron I, Ahmad N, Ravaud P. Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med. 2009;169:1756–1761
  253. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–1516
  254. Horton R. The rhetoric of research. BMJ. 1995;310:985–987
  255. Annals of Internal Medicine. Information for authors. Available at www.annals.org (accessed 15 Jan 2008).
  256. Docherty M, Smith R. The case for structuring the discussion of scientific papers. BMJ. 1999;318:1224–1225
  257. Purcell GP, Donovan SL, Davidoff F. Changes to manuscripts during the editorial process: characterizing the evolution of a clinical paper. JAMA. 1998;280:227–228
  258. Ioannidis JP. Limitations are not properly acknowledged in the scientific literature. J Clin Epidemiol. 2007;60:324–329
  259. Kiviluoto T, Siren J, Luukkonen P, Kivilaakso E. Randomised trial of laparoscopic versus open cholecystectomy for acute and gangrenous cholecystitis. Lancet. 1998;351:321–325
  260. Hupperets MD, Verhagen EA, van Mechelen W. Effect of unsupervised home based proprioceptive training on recurrences of ankle sprain: randomised controlled trial. BMJ. 2009;339:b2684
  261. Garber J, Clarke GN, Weersing VR, Beardslee WR, Brent DA, Gladstone TR, et al. Prevention of depression in at-risk adolescents: a randomized controlled trial. JAMA. 2009;301:2215–2224
  262. Campbell D. Factors relevant to the validity of experiments in social settings. Psychol Bull. 1957;54:297–312
  263. Rothwell PM. Factors that can affect the external validity of randomised controlled trials. PLoS Clin Trials. 2006;1:e9
  264. King M, Nazareth I, Lampe F, Bower P, Chandler M, Morou M, et al. Conceptual framework and systematic review of the effects of participants’ and professionals’ preferences in randomised controlled trials. Health Technol Assess. 2005;9:1-iv
  265. Djulbegovic B, Lacevic M, Cantor A, Fields KK, Bennett CL, Adams JR, et al. The uncertainty principle and industry-sponsored research. Lancet. 2000;356:635–638
  266. Dans AL, Dans LF, Guyatt GH, Richardson S. Users’ guides to the medical literature: XIV. How to decide on the applicability of clinical trial results to your patient. Evidence-Based Medicine Working Group. JAMA. 1998;279:545–549
  267. Smith GD, Egger M. Who benefits from medical interventions?. BMJ. 1994;308:72–74
  268. McAlister FA. Applying the results of systematic reviews at the bedside. In:  Egger M,  Davey Smith G,  Altman DG editor. Systematic reviews in health care: meta-analysis in context. BMJ Books; 2001;
  269. Bartlett C, Doyal L, Ebrahim S, Davey P, Bachmann M, Egger M, et al. The causes and effects of socio-demographic exclusions from clinical trials. Health Technol Assess. 2005;9:iii-x, 1
  270. Bonell C, Oakley A, Hargreaves J, Strange V, Rees R. Assessment of generalisability in trials of health interventions: suggested framework and systematic review. BMJ. 2006;333:346–349
  271. Bornhoft G, Maxion-Bergemann S, Wolf U, Kienle GS, Michalsen A, Vollmar HC, et al. Checklist for the qualitative evaluation of clinical studies with particular focus on external validity and model validity. BMC Med Res Methodol. 2006;6:56
  272. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318:1728–1733
  273. Altman DG. Confidence intervals for the number needed to treat. BMJ. 1998;317:1309–1312
  274. Fanaroff AA, Korones SB, Wright LL, Wright EC, Poland RL, Bauer CB, et al. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med. 1994;330:1107–1113
  275. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet. 1986;2:57–66
  276. Gotzsche PC, Gjorup I, Bonnen H, Brahe NE, Becker U, Burcharth F. Somatostatin v placebo in bleeding oesophageal varices: randomised trial and meta-analysis. BMJ. 1995;310:1495–1498
  277. Clarke M, Hopewell S, Chalmers I. Reports of clinical trials should begin and end with up-to-date systematic reviews of other relevant evidence: a status report. J R Soc Med. 2007;100:187–190
  278. Goodman SN. Toward evidence-based medical statistics. 1: The P value fallacy. Ann Intern Med. 1999;130:995–1004
  279. Gotzsche PC. Reference bias in reports of drug trials. BMJ. 1987;295:654–656
  280. Papp K, Bissonnette R, Rosoph L, Wasel N, Lynde CW, Searles G, et al. Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. Lancet. 2008;371:1337–1342
  281. Dickersin K. How important is publication bias? A synthesis of available data. AIDS Educ Prev. 1997;9:15–21
  282. Song F, Eastwood AJ, Gilbody S, Duley L, Sutton AJ. Publication and related biases. Health Technol Assess. 2000;4:1–115
  283. Williamson PR, Gamble C. Identification and impact of outcome selection bias in meta-analysis. Stat Med. 2005;24:1547–1561
  284. Tramer MR, Reynolds DJ, Moore RA, McQuay HJ. Impact of covert duplicate publication on meta-analysis: a case study. BMJ. 1997;315:635–640
  285. Simes RJ. Publication bias: the case for an international registry of clinical trials. J Clin Oncol. 1986;4:1529–1541
  286. Chalmers I. From optimism to disillusion about commitment to transparency in the medico-industrial complex. J R Soc Med. 2006;99:337–341
  287. Tonks A. A clinical trials register for Europe. BMJ. 2002;325:1314–1315
  288. Dickersin K, Rennie D. Registering clinical trials. JAMA. 2003;290:516–523
  289. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet. 2004;363:1341–1345
  290. De Angelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. Lancet. 2005;365:1827–1829
  291. Zarin DA, Ide NC, Tse T, Harlan WR, West JC, Lindberg DA. Issues in the registration of clinical trials. JAMA. 2007;297:2112–2120
  292. Hopewell S, Altman DG, Moher D, Schulz KF. Endorsement of the CONSORT Statement by high impact factor medical journals: a survey of journal editors and journal ‘instructions to authors’. Trials. 2008;9:20
  293. Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358:877–887
  294. Chan AW, Tetzlaff J, Altman D, Gotzsche PC, Hrobjartsson A, Krleza-Jeric K, et al. The SPIRIT initiative: defining standard protocol items for randomised trials. Oral presentation at the 16th Cochrane Colloquium: Evidence in the era of globalisation; 2008 Oct 3-7; Freiburg, Germany [[abstract]]. Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen. 2008;102:27
  295. Gregson S, Adamson S, Papaya S, Mundondo J, Nyamukapa CA, Mason PR, et al. Impact and process evaluation of integrated community and clinic-based HIV-1 control: a cluster-randomised trial in eastern Zimbabwe. PLoS Med. 2007;4:e102
  296. Shaddy RE, Boucek MM, Hsu DT, Boucek RJ, Canter CE, Mahony L, et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA. 2007;298:1171–1179
  297. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326:1167–1170
  298. Kjaergard LL, ls-Nielsen B. Association between competing interests and authors’ conclusions: epidemiological study of randomised clinical trials published in the BMJ. BMJ. 2002;325:249
  299. Bero L, Oostvogel F, Bacchetti P, Lee K. Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLoS Med. 2007;4:e184
  300. Sismondo S. Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemp Clin Trials. 2008;29:109–113
  301. ls-Nielsen B , Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?. JAMA. 2003;290:921–928
  302. Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA. 2008;299:1800–1812
  303. McAlister FA, Straus SE, Sackett DL, Altman DG. Analysis and reporting of factorial trials: a systematic review. JAMA. 2003;289:2545–2553
  304. Senn S. Crossover trials in clinical research. 2nd ed. Wiley; 2002;
  305. Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, et al. Evaluating non-randomised intervention studies. Health Technol Assess. 2003;7:iii-173
  306. Kunz R, Vist G, Oxman AD. Randomisation to protect against selection bias in healthcare trials. Cochrane Database Syst Rev. 2007;MR000012
  307. Collins R, MacMahon S. Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials. Lancet. 2001;357:373–380
  308. Schulz KF. Randomised trials, human nature, and reporting guidelines. Lancet. 1996;348:596–598
  309. Murray GD. Promoting good research practice. Stat Methods Med Res. 2000;9:17–24
  310. Narahari SR, Ryan TJ, Aggithaya MG, Bose KS, Prasanna KS. Evidence-based approaches for the Ayurvedic traditional herbal formulations: toward an Ayurvedic CONSORT model. J Altern Complement Med. 2008;14:769–776
  311. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. Ann Intern Med. 2003;138:40–44
  312. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147:573–577
  313. Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, Veer M, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360:213–224Cite this as: BMJ 2010;340:c869

 In order to encourage dissemination of the CONSORT 2010 Statement, this article is freely accessible on bmj.com and will also be published in the Journal of Clinical Epidemiology. The authors jointly hold the copyright for this article. For details on further use, see the CONSORt website (www.consort-statement.org).

 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non-commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/and http://creativecommons.org/licenses/by-nc/2.0/legalcode.

PII: S0895-4356(10)00103-4

doi: 10.1016/j.jclinepi.2010.03.004

Journal of Clinical Epidemiology
Volume 63, Issue 8 , Pages e1-e37 , August 2010

Article Tools

* Image Usage & Resolution